P53 is well known to be mutated in high grade osteosarcomas [15, 32] and mutant P53 is often detected by immunohistochemistry (IHC) due to its increased half-life [33], highlighting its potential as a valuable marker for osteosarcoma patient prognosis. Here, TP53 is linked to osteosarcoma.